Predictive factors in patients with EGFR mutation‑negative non‑small cell lung cancer treated with erlotinib

  • Authors:
    • Hidenobu Ishii
    • Koichi Azuma
    • Kazuhiko Yamada
    • Takashi  Kinoshita
    • Youhei Imamura
    • Tomoaki Hoshino
  • View Affiliations

  • Published online on: September 18, 2014     https://doi.org/10.3892/ol.2014.2548
  • Pages: 2699-2704
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Factors predicting the efficacy of erlotinib treatment in patients with EGFR mutation‑negative non‑small‑cell lung cancer (NSCLC) have not been well studied. This retrospective study investigates whether patient characteristics, such as site of metastasis, can predict the efficacy of erlotinib treatment in NSCLC patients. In total, 53 EGFR mutation‑negative NSCLC patients treated with erlotinib were enrolled, and the associations between clinicopathological characteristics and patient survival were analyzed. The EGFR mutation status was determined using the peptide nucleic acid‑locked nucleic acid polymerase chain reaction clamp method. Survival curves were obtained using the Kaplan‑Meier method. Among the NSCLC patients treated with erlotinib, 27 patients with pulmonary metastasis exhibited significantly longer progression‑free survival (PFS) and overall survival (OS) times than those without pulmonary metastasis (median PFS time, 2.9 versus 1.2 months; P=0.0010 and median OS time, 12.4 versus 4.1 months; P=0.0007). Multivariate analyses also revealed that pulmonary metastasis independently correlated with PFS and OS times (hazard ratio, 0.39; P=0.0055 and hazard ratio, 0.33; P=0.0022, respectively). Patients with pulmonary metastasis exhibited significantly longer PFS and OS times than those without pulmonary metastasis. The presence of pulmonary metastasis may be a predictive factor in patients with EGFR mutation‑negative NSCLC treated with erlotinib.
View Figures
View References

Related Articles

Journal Cover

December-2014
Volume 8 Issue 6

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Ishii H, Azuma K, Yamada K, Kinoshita T, Imamura Y and Hoshino T: Predictive factors in patients with EGFR mutation‑negative non‑small cell lung cancer treated with erlotinib. Oncol Lett 8: 2699-2704, 2014
APA
Ishii, H., Azuma, K., Yamada, K., Kinoshita, T., Imamura, Y., & Hoshino, T. (2014). Predictive factors in patients with EGFR mutation‑negative non‑small cell lung cancer treated with erlotinib. Oncology Letters, 8, 2699-2704. https://doi.org/10.3892/ol.2014.2548
MLA
Ishii, H., Azuma, K., Yamada, K., Kinoshita, T., Imamura, Y., Hoshino, T."Predictive factors in patients with EGFR mutation‑negative non‑small cell lung cancer treated with erlotinib". Oncology Letters 8.6 (2014): 2699-2704.
Chicago
Ishii, H., Azuma, K., Yamada, K., Kinoshita, T., Imamura, Y., Hoshino, T."Predictive factors in patients with EGFR mutation‑negative non‑small cell lung cancer treated with erlotinib". Oncology Letters 8, no. 6 (2014): 2699-2704. https://doi.org/10.3892/ol.2014.2548